Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on August 8, 2013. The filing serves to announce the Company's financial results for the second quarter of 2013. The registrant is incorporated in Delaware and maintains its principal executive offices in Bothell, Washington.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1. Consequently, no quantitative financial metrics can be extracted from the body of this 8-K report.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It references the issuance of a press release regarding Q2 2013 results but does not summarize the comparative performance within the text of the 8-K itself.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The text explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (the August 8, 2013 press release) for actual Q2 2013 financial figures, as they are not present in the 8-K text.
- Verify the discrepancy between the request metadata company name ("ACHIEVE LIFE SCIENCES, INC.") and the registrant name in the filing ("ONCOGENEX PHARMACEUTICALS, INC.").
- Confirm the status of the press release to ensure it has not been superseded by subsequent filings.